The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa
study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered
intravenously as adjunctive therapy, therefore in addition to standard of care (SoC)
therapy, to patients with severe community-acquired bacterial pneumonia (sCABP).
The completion of this study will contribute to the basic knowledge on stem cells and their
mode-of-action, and has a large translational character, i.e. to document the safety and
explore the efficacy of Cx611 in patients with sCABP.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
TiGenix S.A.U.
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Centre Hospital Regional Universitaire de Limoges Cliniques universitaires Saint-Luc- Université Catholique de Louvain European Commission Hospital San Carlos, Madrid